ANNUAL REPORT 2012 - TiGenix

Notes
(1)
The extraordinary shareholders’ meeting of May 13, 2005 extended the exercise period until May 13, 2014.
(2)
2,118 warrants have expired as they have not been granted and 22,130 warrants have lapsed due to their beneficiary leaving the
Company. 6,790 warrants have been exercised and are therefore no longer outstanding.
(3)
152,765 warrants have expired as they have not been granted and 8,142 warrants have lapsed due to their beneficiary leaving
the Company.
(4)
118,500 warrants have expired as they have not been granted; 103,750 warrants have expired as they have not been accepted by
their beneficiary and 67,937 warrants have lapsed due to their beneficiary leaving the Company.
(5)
38,000 warrants have expired as they have not been accepted by their beneficiary and 73,000 warrants have lapsed due to their
beneficiary leaving the Company. 2,500 warrants have been exercised and are therefore no longer outstanding.
(6)
267,800 warrants have expired as they have not been granted; 62,000 warrants have expired as they have not been accepted by
their beneficiary and 27,275 warrants have lapsed due to their beneficiaries leaving the Company.
(7)
4,500 warrants have expired as they have not been granted; 123,500 warrants have expired as they have not been accepted by
their beneficiary and 59,250 warrants have lapsed due to their beneficiary leaving the Company.
(8)
52,000 warrants have expired as they have not been accepted by their beneficiary and 26,000 warrants have lapsed due to their
beneficiary leaving the Company.
On December 31, 2012, the total number of all outstanding warrants that have already been
granted, is 5,617,683, which represents approximately 5.30 % of the total number of all issued and
outstanding voting financial instruments, as shown in section 5.7.
5.7. OUTSTANDING FINANCIAL INSTRUMENTS
The table below provides an overview of
the issued and outstanding voting financial
instruments, whether or not representing
the Company’s share capital on December
31, 2012 (1) . The overview must also be read
together with the notes referred to below.
Number %
A Issued shares 100,288,586 94.70 %
B Shares to be issued upon the exercise of all outstanding warrants (2) 5,617,683 5.30 %
C Total (A)+(B) 105,906,269 100.00 %
Notes
(1)
On March 20, 2013, an extraordinary shareholders’ meeting will be asked to decide on the issue of 777,000 new warrants. These
new warrants, if effectively issued, are not included in the above overview of issued and outstanding voting financial instruments.
(2)
As at December 31, 2012.
44 TiGenix I annual report 2012